-+ 0.00%
-+ 0.00%
-+ 0.00%

Keensight-backed Isto Biologics acquires synthetic bone graft maker NovaBone from Halma

PUBT·08/04/2026 07:14:52
Listen to the news
Keensight-backed Isto Biologics acquires synthetic bone graft maker NovaBone from Halma
  • Isto Biologics acquired NovaBone from Halma to expand its synthetic bone graft substitutes portfolio.
  • The deal adds NovaBone’s bioactive glass technology platform to Isto’s bone-healing product lineup.
  • NovaBone, founded in 2002, is headquartered in Alachua, Florida, with products sold in more than 40 countries.
  • Keensight Capital-backed Isto described the acquisition as its first strategic deal since Keensight’s investment about 10 months ago.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keensight Capital SAS published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.